Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Versartis Inc (NASDAQ:VSAR)

15.45
Delayed Data
As of 9:37am ET
 +0.35 / +2.32%
Today’s Change
6.17
Today|||52-Week Range
16.55
+3.69%
Year-to-Date
Versartis' Pipeline Holds Big Promise
Jan 13 / TheStreet.com - Paid Partner Content
Adamas Pharmaceuticals (ADMS) in Focus: Stock Up 5.4%
Jan 09 / Zacks.com - Paid Partner Content
Versartis' Pipeline Holds Big Promise
Jan 13 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close15.10
Today’s open15.60
Day’s range15.10 - 15.87
Volume9,299
Average volume (3 months)160,259
Market cap$525.4M
Dividend yield--
Data as of 9:37am ET, 01/20/2017

Growth & Valuation

Earnings growth (last year)+35.31%
Earnings growth (this year)-16.55%
Earnings growth (next 5 years)--
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book2.52

Competitors

 Today’s
change
Today’s
% change
SCMPSucampo Pharmaceutic...-0.02-0.22%
SCLNSciClone Pharmaceuti...0.000.00%
RETAReata Pharmaceutical...+0.03+0.13%
HSKAHeska Corp-0.27-0.35%
Data as of 9:52am ET, 01/20/2017

Financials

Next reporting dateFebruary 23, 2017
EPS forecast (this quarter)-$0.83
Annual revenue (last year)$0.00
Annual profit (last year)-$82.2M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Jay P. Shepard
Chief Financial Officer &
Head-Investor Relations
Joshua T. Brumm
Corporate headquarters
Menlo Park, California

Forecasts


Search for Jobs